Skip to main content
. 2023 Jan 10;8(1):e157421. doi: 10.1172/jci.insight.157421

Figure 7. Effect of TKI treatment on murine leukemic LT-HSCs.

Figure 7

BM cells from SCL-tTA mice (CD45.2) were transplanted into lethally irradiated recipients (CD45.1) and maintained without doxycycline, resulting in development of CML after 8 weeks, then treated with vehicle (CML) or nilotinib (50 mg/kg/d) (CML+TKI) for 14 days. MFI of surface c-KIT levels on donor LT-HSC cells (A) and frequency (B) and absolute number (C) of donor c-KITlo and c-KIThi LT-HSCs in CML and CML+TKI mice (n = 9–10). Experimental design: 1 × 106 CML (CD45.1/CD45.2) and normal (CD45.2) BM cells were transplanted into lethally irradiated recipient mice (CD45.1). After 8 weeks, mice were treated with vehicle (Ctrl), SCF (100 μg/kg/d), nilotinib (50 mg/kg/d) (NIL) or SCF and nilotinib combination (COMBO) for 14 days (D). Spleen weights (E), total BM cellularity (F), BM CML LSK cells (G), BM CML LT-HSCs (H), BM CML ST-HSCs (I), BM CML MPP (J), and BM CML GMP (K) numbers after treatment (n = 6–7 per arm). Data represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, based on 2-way ANOVA with Tukey’s test (C) and 1-way ANOVA (E–J).